
Work Here?
Brightseed uses AI to find beneficial bioactive compounds in plants and microbes that can support health. Its Forager® platform analyzes natural molecules and links their effects to human biology and the microbiome. The company partners with food, beverage, and supplement brands and has a product called Brightseed™ Bio Gut Fiber, a dietary fiber that contains bioactives shown to support gut health. The goal is to identify and apply nature-derived compounds to healthier foods and supplements, expanding options for wellness products.
Industries
Food & Agriculture
Data & Analytics
Consumer Software
Biotechnology
Company Size
11-50
Company Stage
Grant
Total Funding
$127.3M
Headquarters
San Francisco, California
Founded
2017
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$127.3M
Above
Industry Average
Funded Over
7 Rounds
Hybrid work flexibility
Medical, dental, & vision
Unlimited PTO
Life insurance
EAP
401(k) plan
Mental health platform
Employee discounts
Cell phone & commuter costs
Parental leave
Brightseed unveils "world-first" clinically validated AI platform for plant bioactives discovery. * 26 March 2026 * colind88 * News Feed Specializing in the AI-driven discovery of new plant bioactives, Brightseed has launched an Innovation Platform to help convey more information about these novel ingredients and their health benefits for product applications. It is designed to accelerate the development and commercialization of products containing these clinically validated compounds - accelerating their pathway to market. Brightseed has dubbed its core proprietary AI-powered discovery engine, Forager, the world's largest proprietary bioactive data bank. It spans more than 11 million natural compounds across 23 health territories. Positioning itself apart from general AI systems trained on public data, Brightseed's platform harnesses the company's own proprietary biological intelligence "designed specifically for scientific rigor, traceability, and defensibility." "Health innovation has operated on a broken probability curve for decades," says Lee Chae, Ph.D., co-founder and CEO of Brightseed. "We built the Brightseed Innovation Platform to fundamentally change that curve." "By converging deep biological insight, proprietary multi-omics data assets, and cutting-edge AI and machine learning architecture into a continuous innovation foundation, we are defining a new category - one where AI is not an add-on, but the core operating foundation of life sciences innovation." Tackling fragmented R&D. Across health and life sciences, Brightseed underlines that more than 75% of early product ideas fail to reach market due to fragmented workflows, disconnected data, and late-stage risk discovery. "Innovation has historically been structured as episodic project work rather than a connected, compounding capability," highlights the company. The Brightseed Innovation Platform is designed to connect discovery, development, and commercialization within a "unified architecture" that preserves scientific insight, evidence, and decision context across the innovation lifecycle. One recently discovered naturally occurring bioactive blend - which Brightseed commercialized as its ingredient BioMetaControl - was found to potentially stabilize glucose levels among adults weaning off GLP-1 medications, while improving glycemic control markers in prediabetic adults. BioMetaControl launched following Brightseed's release of the ingredient Bio Gut Core, which is designed to strengthen the gut barrier and provide relief from bloating and belly pain. Expanding partnerships. Brightseed leverages Rapid Profiling to quickly supply actionable insights on ingredients' phytochemical and bioactive composition in six to eight weeks, which accelerates the clinical validation and commercialization process. With more than 40 partnerships across consumer health, nutrition, personal care, pharmaceuticals, and animal health, the company is transitioning its clients toward a recurring subscription model on its platform. Previously, Brightseed and UK-based consumer healthcare business Haleon joined forces to advance the discovery of plant-based, small molecules that can improve human health. The Innovation Platform's launch is timely, as Brightseed highlights that consumers are willing to pay more for products containing bioactives. Its latest market research indicates that "bioactivists" are the largest and fastest-growing health segment among US consumers, growing from 27% to 45% between 2022 and 2025.
Brightseed has launched what it calls the world's first clinically-validated, enterprise AI platform for health sciences innovation. The South San Francisco-based company is transitioning from a bioactives discovery firm to a platform-based enterprise AI company offering data-as-a-service. The platform addresses a sector challenge where over 75% of early product ideas fail to reach market. At its core is Forager, an AI discovery engine built on a proprietary dataset of more than 11 million natural compounds across 23 health territories. Brightseed currently has over 40 partnerships across consumer health, nutrition, personal care, pharmaceuticals and animal health. The company is moving customers to a recurring subscription model as it targets the $6.8 trillion global wellness market. The platform connects discovery, development and commercialisation within a unified system.
Brightseed, a biotech startup using AI to discover natural bioactive compounds, announced results from a peer-reviewed clinical trial showing its BioMetaControl supplement significantly improved glycaemic control in adults with prediabetes. The study was published in Bioactive Compounds in Health and Disease. The four-week trial involved 126 adults with prediabetes who received either a supplement containing 120 mg/day of N-trans caffeoyltyramine and N-trans feruloyltyramine or a placebo. Participants taking the bioactives experienced statistically significant reductions in fasting blood glucose compared to placebo, along with improvements in fasting insulin and postprandial glucose response. The compounds were identified through Brightseed's AI-powered discovery engine and act as potent agonists of hepatocyte nuclear factor 4 alpha, which plays a role in glucose regulation. No adverse events were reported.
Brightseed has launched Bio Gut Core, which has been shown to strengthen the gut barrier and reduce bloating and abdominal pain in a new human clinical trial.
[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Brightseed.]Brightseed, a startup harnessing AI to discover plant bioactives, has launched Bio Gut Core, a nutraceutical containing NCT and NFT, two compounds found to improve gut barrier function in a recent human clinical trial.A compromised gut barrier may lead to a “leaky gut,” which is associated with dysbiosis, inflammation, and poor nutrient absorption along with bloating, gas, diarrhea, and constipation, claims Brightseed.“The gut barrier acts like a protective shield in the digestive system, providing a thriving environment for the gut microbiome, ensuring optimal nutrient absorption, and filtering out toxic and undesirable elements. Until now, supplements targeting gut barrier function have required unfeasibly large doses while delivering questionable results.”“Competing supplements require 3-5g per dose, whereas Bio Gut Core delivers a low-dose (120mg), easy to formulate alternative that is clinically backed.”Brightseed has previously supplied NFT and NCT (N-trans-caffeoyl tyramine and N-trans-feruloyl tyramine), via Bio Gut Fiber, an ingredient sourced from upcycled hemp hulls. The new Bio Gut Core product is a high-purity powder blend of NFT and NCT produced via precision fermentation, enabling the ingredients to be used in a wider range of products, a spokesperson told AgFunderNews.“Bio Gut Core features NCT and NFT with higher potency optimized for efficacy. It is easy to formulate across multiple applications, including capsules, tablets, soft gels, ready-to-mix, and ready-to-drink products.”The spokesperson added: “We have received interest from existing and prospective customers. Even in this pre-launch period, customer demand has far outpaced our expectations from innovators across the food, beverage, supplement, and digestive health space.”Leaky gutA double-blinded, randomized, placebo-controlled clinical trial, which Brightseed says should be published in a peer-reviewed journal this summer, showed that NCT and NFT can help maintain the integrity of the gut barrier, enabling the uptake of essential nutrients but keeping out unwanted pathogens.Subjects also reported a reduction in bloating and belly pain after three weeks of supplementation with a [daily] 120mg dose of Bio Gut Core, said the spokesperson.Asked what claims companies can make on pack, the spokesperson said: “While product specific claims are to be decided and evaluated by each customer, a few example claims include, ‘Clinically shown to improve gut barrier integrity compared to placebo in less than a month’ or ‘Bio Gut Core is clinically shown to provide a stronger gut barrier and relief from bloating and belly pain within three weeks.'”AI-powered discoveryLaunched by Sofia Elizondo, Dr Lee Chae, and Dr Jim Flatt in 2017, Brightseed has built a vast database of plant-based compounds associated with biological targets. Its AI-powered Forager platform then predicts how previously untapped plant components might confer specific health benefits and helps identify the optimal way to source or produce them at commercial scale.This might mean extracting them from a plant source or by understanding the metabolic pathways that plants use to produce these compounds and then using those pathways as a blueprint for producing them via precision fermentation, for example.To maximize its potential, Brightseed is both developing its own bioactives such as NFT and NCT and working with a wide range of partners including Haleon, Ocean Spray and Danone on other projects.Some of Brightseed’s partners are looking to discover and commercialize new bioactives, while others are looking to learn more about the composition and health benefits of products that may already be in their portfolios, explained CCO Sofia Elizondo in a recent interview with AgFunderNews
Find jobs on Simplify and start your career today
Industries
Food & Agriculture
Data & Analytics
Consumer Software
Biotechnology
Company Size
11-50
Company Stage
Grant
Total Funding
$127.3M
Headquarters
San Francisco, California
Founded
2017
Find jobs on Simplify and start your career today